Cart
sales@molnova.com
Suptavumab
CAS No. 1629615-23-1
Suptavumab( —— )
Catalog No. M36790 CAS No. 1629615-23-1
Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 629 | In Stock |
|
| 10MG | 943 | In Stock |
|
| 25MG | 1397 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSuptavumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSuptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
-
DescriptionSuptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorRSV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1629615-23-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sim?es EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408. ?
molnova catalog
related products
-
(R)-Lisofylline
(R)-Lisofylline is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 μM).
-
Galiellalactone
A small molecule, direct STAT3 inhibitor that inhibits the IL-6-induced SEAP expression with IC50 of 200-500 nM.
-
2-NP
2-NP increased the duration of STAT1 tyrosine phosphorylation in response to IFN-gamma, and this may underlie its enhancement of STAT1-dependent transcription.
